![]() It will only receive aggregate, anonymized data to understand the success of the offering. John Hancock does not receive any individual test results from GRAIL. You may incur additional costs for diagnostic screenings recommended by your healthcare provider. There is no coordination between John Hancock and any other health plan you may be enrolled in. ![]() John Hancock does not provide medical advice, is not involved in the design or manufacture of the Galleri test and is not responsible for the accuracy or performance of the Galleri test. John Hancock is not an affiliate of GRAIL. The test is manufactured and distributed by GRAIL. Galleri is a registered trademark of GRAIL, LLC ("GRAIL"). ![]() Cancer Death Rate Has Dropped by a Third Since 1991. The John Hancock Vitality Program is constantly growing and evolving with advances in science to make cutting-edge technology and information available to customers to help them live longer, healthier, better lives.Ībbott, B. Offering access to the Galleri test builds on existing Vitality program features that encourage customers to take part in recommended preventative care, including mammograms and other cancer screenings, annual physical exams, dental visits, and more. “We are thrilled to see the success of the pilot program and look forward to continuing to work with the leadership at John Hancock as it expands its multi-cancer early detection offering, with the goal of ultimately reducing the burden of cancer and keeping cancer from claiming even more lives.” “The expansion of this first-of-its-kind program shows the benefits of bringing together two industries that share a common goal of improving health outcomes,” said Bob Ragusa, Chief Executive Officer at GRAIL. We’re proud to bring this technology to our customers.” “Early detection, through tests like Galleri, is a way to write a different story to a cancer diagnosis. “Every day counts for cancer patients and their families,” said Lindsay Hanson, Vice President, Head of Behavioral Insurance, Global Strategy and Delivery. The program covers a broad spectrum of activities - including exercise, nutrition, sleep and mindfulness - and rewards customers for the steps they take to stay healthy.īased on the successful customer uptake during the pilot, John Hancock decided to expand access to the Galleri test, following a similar model, to all eligible John Hancock Vitality PLUS customers, while exploring other potential expansions for the future. The John Hancock Vitality Program combines life insurance with a technology-enabled program that offers education, support, incentives, and rewards designed to help and encourage customers to live healthier lives. As a life insurer, we are deeply committed to helping our customers live longer, healthier, better lives and we know that preventative care and early detection are key components of that mission.” We believe there is a critical need to expand awareness of and access to this type of groundbreaking technology. “However, our work with GRAIL runs much deeper than just making Galleri accessible to our customers. It was always our intention to expand beyond the pilot phase and we are thrilled to see this vision come to life,” said Brooks Tingle, President and CEO of John Hancock Insurance. “The initial pilot exceeded our expectations in terms of the number of tests requested, validating our hypothesis that our customers want access to this level of insight into their health. The ACS cites better early detection, among other advances, as a driving factor in reducing the death rate by a third since 19911. According to the American Cancer Society (ACS), cancer is the second leading cause of death in the United States with 610,000 deaths estimated to occur in 2023. For the majority of these cancer types, there are no alternative screening options available. Galleri is the first-of-a-kind test available for detection of a shared cancer signal across more than 50 cancer types that can be localized to specific tissues or organs to help clinicians focus their diagnostic evaluation. The expanded access comes after John Hancock became the first life insurance carrier to make the breakthrough screening technology available to a pilot group of customers in September 2022. Carrier previously became the first life insurer to offer access to the Galleri test through a pilot in 2022īOSTON (February 23, 2023) – Today, John Hancock, a unit of Manulife (NYSE: MFC), announced it will expand access to GRAIL’s Galleri® multi-cancer early detection test to eligible life insurance customers participating in the John Hancock Vitality PLUS program, a significant milestone in John Hancock’s ongoing efforts to help customers live longer, healthier, better lives.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |